Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2551]

UK's NICE gives go ahead for nivolumab for advanced lung cancer

UK's NICE gives go ahead for nivolumab for advanced lung cancer

People with HIV who smoke are more likely to die from lung cancer than from HIV itself

People with HIV who smoke are more likely to die from lung cancer than from HIV itself

FDA approves first biosimilar for the treatment of cancer

FDA approves first biosimilar for the treatment of cancer

Researchers identify possible new target against lung cancer

Researchers identify possible new target against lung cancer

ESMO 2017: 'Triggers': A new tool to assess cancer patients' palliative needs

ESMO 2017: 'Triggers': A new tool to assess cancer patients' palliative needs

'Epigenetic' changes from cigarette smoke may be first step in lung cancer development

'Epigenetic' changes from cigarette smoke may be first step in lung cancer development

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

ESMO 2017: Combination immunotherapy in second/third line extends mesothelioma survival to 15 months

ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

ESMO 2017: Durvalumab improves progression-free survival in stage III lung cancer

ESMO 2017: Durvalumab improves progression-free survival in stage III lung cancer

More from ecancer